US stocks 2026: Moderna, SanDisk lead top 10 gainers delivering up to 734% returns
Ten US stocks with market caps above $5 billion have seen share prices more than triple in 2026, delivering returns up to 734%. Healthcare and tech sectors dominate, led by biotechnology firm Moderna and flash memory maker SanDisk, highlighting strong momentum across biotech and established tech majors like Dell.
US stocks have delivered strong returns in 2026, with at least 10 companies valued at more than $5 billion seeing their share prices more than triple this year. Healthcare and technology stocks have dominated the list of biggest winners, with gains ranging from 234% to 734%, according to market data.Biotechnology company Moderna leads the rankings, followed by flash memory maker SanDisk and cancer treatment developer Iovance Biotherapeutics.
Seven of the 10 biggest gainers belong to the healthcare sector, while the remaining three are technology companies.US MarketsPowered ByAs on 22 Oct 2026, 01:30 AM ISTS&P 500 Top GainersSuper Micro Computer35.57(9.55%)Charles River344.87(9.33%)Datadog273.09(6.50%)Dell Technologies485.88(5.27%)Gainers»S&P 500 Top LosersCoterra Energy32.56(-8.62%)AT&T21.91(-6.45%)DexCom80.26(-6.39%)Netflix65.04(-5.31%)Losers»The rankings consider year-to-date price returns of US-listed companies with a market cap above $5 billion and exclude American Depositary Receipts (ADRs).Moderna has emerged as the biggest winner, with shares soaring 733.54% from $29.49 at the end of last year to $245.81.
The healthcare company now commands a market cap of $98.1 billion, making it the only stock among the top 10 to deliver a gain exceeding 700%.SanDisk occupies second place with a return of 480.60%. Its shares have climbed from $237.38 to $1,378.22, taking the memory storage company's market cap to $200.3 billion. SanDisk is among the three technology stocks featuring in the rankings.Live EventsIovance Biotherapeutics, which develops cancer immunotherapies, ranks third after delivering a 435.53% return.
Its shares have risen from $2.73 to $14.62, giving the company a market value of $6.6 billion. The rally highlights the strong performance of select biotechnology companies this year.Two other healthcare companies have generated returns exceeding 350%. Twist Bioscience, a synthetic biology company, has advanced 370.15%, with its stock rising from $31.72 to $149.13. The company is now valued at $9.9 billion.10x Genomics, which develops tools used in biological research, follows closely with a gain of 363.46%.
Its shares have surged from $16.31 to $75.59, taking its market cap to $9.8 billion.ImmunityBio is sixth on the list after its shares gained 336.36%. The cancer immunotherapy company's stock has climbed from $1.98 to $8.64, valuing it at $9.2 billion. Its performance adds to the dominance of healthcare stocks among this year's largest gainers.Technology company MaxLinear follows with a 334.83% return.
The semiconductor manufacturer's shares have risen from $17.43 to $75.79, giving it a market value of $6.9 billion.Erasca, another biotechnology company focused on cancer treatments, has gained 289.52%, with its shares climbing from $3.72 to $14.49. With a market cap of $5.1 billion, it is the smallest company by market value among the 10 stocks.Dell Technologies, one of the largest companies in the rankings, has delivered a 285.99% return.
Its shares have surged from $125.88 to $485.88, lifting its market cap to $308.9 billion. Dell's presence shows that substantial gains have extended beyond smaller biotechnology businesses to established technology companies.Completing the top 10 is Corcept Therapeutics, whose stock has advanced 234.14% from $34.80 to $116.28. The healthcare company commands a market cap of $12.6 billion.The rankings show a striking concentration of gains in healthcare, particularly biotechnology, alongside selected technology businesses.
The seven healthcare companies on the list have delivered returns ranging from 234% to 734%.Disclosure: This article has been written by Podishetti Akash, who is not a SEBI-registered Research Analyst or an Investment Adviser. Podishetti Akash and his ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication.
The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclosures here.(You can now subscribe to our ETMarkets WhatsApp channel)
